Skip to content
Back to resident companies

Drūl

Investment areas

  • Biotech / Life Sciences
Founders & Leadership
Brent Ifemembi
Nelson Ndahiro
Headquarters
Cambridge, MA

The new standard in oral care.

The Tough Tech problem we are solving

Oral dysbiosis, an imbalanced oral microbiome, is linked to chronic diseases like gum disease, diabetes, heart disease, and neurodegenerative disorders, affecting hundreds of millions worldwide. While molecular screening promises early detection and intervention, current tests are slow, inaccessible, and clinic-bound, leading to delayed care, poor outcomes, and overwhelming healthcare costs. A rapid, at-home platform is urgently needed to make proactive oral-systemic health monitoring routine, transforming preventive medicine.

About our solution

Drūl delivers a compact hardware device that analyzes saliva to detect oral microbiome dysbiosis in minutes, starting with gum disease and tooth decay risk for 200 million Americans. By uncovering the oral cavity's overlooked role as a gateway to systemic health, our data-driven platform identifies early biomarkers for oral cancers, diabetes, and neurological disorders—empowering users with actionable insights, faster treatment, and reduced chronic disease burden through accessible, precision care